2025-04-19 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**0. Key Figures & Initial Analysis:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The provided data shows significant underperformance compared to the S&P 500 (VOO).  While MRK's cumulative return is positive, it lags substantially behind the benchmark index. Further analysis is needed to determine the underlying causes.

**1. Performance Comparison & Divergence:**

* **MRK Cumulative Return:** 22.34%
* **VOO (S&P 500) Cumulative Return:** 76.18%
* **Return Difference:** -53.8%
* **Relative Divergence:** 24.8% (This indicates MRK's performance is in the 24.8th percentile relative to its historical performance against VOO, based on the provided min and max divergence.)

The significant negative divergence highlights MRK's underperformance relative to the broader market.  Further investigation is required to understand if this is due to company-specific factors or broader market trends.

The provided CAGR (Compound Annual Growth Rate) and MDD (Maximum Drawdown) data shows fluctuating performance over the years. Alpha values, though positive in some periods, are not consistently high, suggesting limited outperformance compared to the market (Beta).


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 58.6% | -22.0% | 0.1 | 108.6 |
| 2016-2018  | 49.0% | 66.4% | 27.0% | 0.4 | 151.9 |
| 2017-2019  | 48.0% | 66.4% | 14.0% | 0.9 | 185.8 |
| 2018-2020  | 26.0% | 66.4% | -4.0% | 0.7 | 172.4 |
| 2019-2021  | 4.0% | 65.6% | -56.0% | 0.5 | 175.4 |
| 2020-2022  | 20.0% | 69.3% | 11.0% | 0.5 | 262.1 |
| 2021-2023  | 43.0% | 69.3% | 22.0% | 0.3 | 264.8 |
| 2022-2024  | -3.0% | 69.3% | -24.0% | 0.2 | 248.2 |
| 2023-2025  | -47.0% | 70.2% | -62.0% | 0.2 | 196.3 |


**2. Recent Price Movement:**

* **Closing Price:** $78.0
* **5-day Moving Average:** $78.24
* **20-day Moving Average:** $84.02
* **60-day Moving Average:** $88.94

The price is below all three moving averages, suggesting a possible downward trend.  The recent price increase of $2.01 (from $76.46) could signal a short-term bounce but needs further confirmation.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4244 (Medium Risk)
* **RSI:** 27.13 (Suggests oversold conditions)
* **PPO:** -0.781 (Negative, indicating bearish momentum)
* **20-Day Relative Divergence Change:** +2.0 (Short-term upward trend)
* **Expected Return (Long-Term, >2 years):** -11.7% (Underperformance relative to S&P 500)

The combination of low RSI, negative PPO, and negative expected return indicates a bearish outlook, although the recent price increase and short-term upward divergence offer a slightly more optimistic near-term view.  The MRI suggests moderate risk.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2024-11-06 | 1.25  | $16.66 B      |
| 2024-08-05 | 2.15  | $16.11 B      |
| 2024-05-03 | 1.88  | $15.78 B      |
| 2023-11-03 | 1.87  | $15.96 B      |
| 2024-11-06 | 1.87  | $15.96 B      |

There appears to be a duplication in the data for November 6th, 2024.  EPS shows some volatility, with a significant drop in the last reported quarter. Revenue remains relatively stable.  Further investigation is needed to understand the reasons behind the EPS fluctuation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |

Revenue is relatively stable, while profit margins are high and generally consistent, although there is a slight decline in the most recent quarter.


**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $46.31B    | 8.08%         |
| 2024-09-30 | $44.50B    | 7.09%         |
| 2024-06-30 | $43.58B    | 12.52%        |
| 2024-03-31 | $40.36B    | 11.80%        |
| 2023-12-31 | $37.58B    | -3.26%        |

Equity is growing steadily, but ROE shows significant volatility. The negative ROE in 2023-12-31 warrants further investigation.

**6. Overall Analysis:**

Merck (MRK) currently exhibits mixed signals. While the company shows strong profitability and a generally stable revenue stream, its stock price underperforms the S&P 500 significantly.  Technical indicators point to a bearish outlook, though the recent price increase and oversold RSI suggest potential for a short-term bounce.  The volatility in EPS and ROE requires further investigation. Long-term investors should carefully consider the negative expected return relative to the market before committing to a significant investment.  A deeper dive into the reasons for the underperformance (e.g., specific product performance, regulatory issues, competitive pressures) is crucial before making any investment decisions.
